ProQR Therapeutics (NASDAQ:PRQR – Get Rating) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,330,000 shares, an increase of 16.7% from the February 13th total of 1,140,000 shares. Based on an average daily volume of 2,730,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 2.9% of the shares of the stock are sold short.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. Raymond James lifted their target price on shares of ProQR Therapeutics from $2.00 to $5.00 and gave the stock an “outperform” rating in a research note on Friday, December 23rd. Cantor Fitzgerald raised shares of ProQR Therapeutics from a “neutral” rating to an “overweight” rating and set a $5.00 target price on the stock in a research note on Thursday, December 22nd. Finally, StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $3.90.
ProQR Therapeutics Trading Up 7.8 %
Shares of PRQR stock opened at $3.16 on Wednesday. The company’s 50-day moving average price is $3.04 and its 200-day moving average price is $1.87. The company has a current ratio of 3.86, a quick ratio of 3.86 and a debt-to-equity ratio of 0.07. The stock has a market cap of $225.28 million, a price-to-earnings ratio of -2.93 and a beta of 0.12. ProQR Therapeutics has a twelve month low of $0.53 and a twelve month high of $3.78.
Institutional Inflows and Outflows
About ProQR Therapeutics
ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa.
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.